TP53 and pancreatic ductal adenocarcinoma: TP53 mutations are a prominent feature of pancreatic ductal adenocarcinoma (PDAC), a lethal disease also dominated by frequent mutations in other well-established driver genes including oncogenic mutations in KRAS  and inactivating mutations in the cell cycle inhibitor CDKN2A and/or the TGF-β pathway effector SMAD421.